Guardant Health, Inc.
https://www.guardanthealth.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Guardant Health, Inc.
Minute Insight: Hedera DX Completes €14m Raise To Fund ML-Backed Liquid Biopsy Tech
Hedera DX’s liquid biopsy test uses machine learning to recommend drugs to patients based on a tumor’s circulating DNA profile.
Minute Insight: Guardant Launches Shield Test To Detect Colorectal Cancer In Average-Risk Adults
The Shield lab-developed test was validated in a 309-patient study, demonstrating 91% sensitivity for colorectal cancer. The company is sponsoring the ECLIPSE study to support a PMA for the test.
JPM 2022 Mid-Week IVD Roundup: Guardant, Illumina, Ortho Clinical, Thermo Fisher
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022. Here are some highlights from the in vitro diagnostics companies that presented on the first two days of the meeting.
Guardant Reports Record Q3 Sales And A Buy Back From Softbank
Strong oncology sales have driven the company’s revenues to new heights, keeping it on target to meet its yearly revenue guidance.
Company Information
- Industry
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Other Names / Subsidiaries
-
- Guardant